Medicine Price Control in India: Why Can the Same Cancer Drug Have Such Different Prices?

Cancer treatment is often associated with difficult medical decisions, prolonged hospital visits and emotional uncertainty. For many Indian families, however, the financial burden can become an additional source of distress. The cost of a prescribed medicine may vary substantially depending on its brand, manufacturer, formulation, pharmacy, hospital procurement system and availability of lower-priced alternatives. When patients discover that medicines containing the same active ingredient are being sold at markedly different prices, an important question emerges: why does this happen in a country that regulates the prices of essential medicines?

India has established mechanisms to prevent excessive medicine pricing, including the National Pharmaceutical Pricing Authority (NPPA), the Drug Price Control Order (DPCO) and the National List of Essential Medicines (NLEM). These frameworks help regulate the prices of selected medicines and establish rules for manufacturers and sellers. However, price regulation does not mean that every medicine is sold at one uniform price across the country.

Cancer medicines make this distinction particularly important. Some are covered by price-control provisions, while others may fall outside specific ceilings or have limited competition. A medicine may also be available in multiple strengths, dosage forms and brands, each with different pricing arrangements. In addition, the final amount paid by a patient can include costs beyond the medicine’s listed price.

Understanding these differences requires examining how medicine price controls work, how pharmaceutical markets operate and why the same treatment can place very different financial demands on patients.

Understanding Medicine Price Control in India

The role of the National Pharmaceutical Pricing Authority

The National Pharmaceutical Pricing Authority is the government body responsible for implementing and enforcing pharmaceutical price-control measures under the applicable framework. It operates under the Department of Pharmaceuticals and plays an important role in determining or monitoring prices for medicines covered by the relevant rules.

The primary purpose of price regulation is to make essential medicines more affordable while maintaining a functioning pharmaceutical supply system. Without safeguards, a company with limited competition or substantial market power may have considerable freedom to set prices. For patients who require continuous treatment, particularly for serious conditions such as cancer, the consequences of high prices can be severe.

However, the NPPA does not automatically set a single national retail price for every medicine sold in India. The applicable rules depend on the medicine, its inclusion in the relevant schedules, the dosage strength, the formulation and the regulatory provisions in force. Some products are subject to ceiling prices, while others may be governed by different pricing rules or remain outside direct ceiling-price regulation.

This distinction is essential because a medicine’s high price does not, by itself, prove that the seller has violated the law. The relevant question is whether the medicine falls under a particular price-control provision and whether the price charged complies with the applicable requirements.

How the Drug Price Control Order works

The Drug Price Control Order provides the regulatory framework for controlling prices of specified medicines. Under the framework associated with DPCO 2013, scheduled formulations are subject to ceiling prices determined using the prescribed methodology. Broadly, this approach uses market-price information for qualifying brands and manufacturers of the relevant formulation, rather than simply choosing the lowest-priced product available.

Once a ceiling price applies, manufacturers must comply with the applicable limit and related requirements. The permitted maximum price is not necessarily the same as the actual selling price of every brand, because companies may charge less than the ceiling. The ceiling establishes an upper regulatory boundary for the covered formulation, subject to the order’s rules and conditions.

The distinction between a ceiling price and a fixed price is important. A ceiling does not require all manufacturers to sell at exactly the same amount. One company may choose a lower price to compete for market share, while another may sell closer to the permitted limit. As a result, patients may still encounter different prices even when products fall under price control.

Medicines outside the scheduled categories may be subject to other provisions, including rules concerning price increases for non-scheduled formulations. The existence of such rules, however, should not be interpreted as a universal price cap across every medicine or every cancer treatment.

Why the National List of Essential Medicines matters

The National List of Essential Medicines identifies medicines considered important for addressing the healthcare needs of the population, based on criteria that include public-health relevance, safety, efficacy and comparative cost-effectiveness. Inclusion in the list can have significant consequences for price regulation because medicines included in the relevant list may become subject to the applicable scheduled-price controls.

However, not every medicine used in cancer care is necessarily included in the NLEM, and inclusion should not be assumed for every brand, formulation or newer treatment. Cancer treatment changes over time as new therapies become available, including targeted medicines and immunotherapies. Their regulatory status may differ from that of established medicines used in chemotherapy or supportive care.

This creates a complex landscape. Two medicines prescribed for the same cancer may be subject to different pricing rules because they contain different active ingredients or belong to different regulatory categories. Even products containing the same ingredient may require careful comparison of strength, dosage form and applicable price notifications before their prices can be evaluated accurately.

Why Can the Same Cancer Drug Have Different Prices?

Brand-name medicines and generic alternatives

One of the most significant reasons for price variation is the difference between branded and generic medicines. A branded medicine is marketed under a particular trade name, while a generic medicine generally uses the same active pharmaceutical ingredient as an established medicine, subject to applicable quality and regulatory requirements.

India has a large pharmaceutical manufacturing industry, including companies that produce generic medicines for domestic and international markets. When multiple manufacturers supply the same active ingredient, competition can create opportunities for lower prices. However, the presence of several brands does not guarantee that every product will be priced similarly.

A brand may command a higher price because of its market position, established relationships with hospitals and prescribers, promotional expenditure or distribution strategy. A generic manufacturer may adopt a lower-price approach to attract customers, while another company may focus on a particular segment of the market. These commercial decisions can produce substantial price differences between products containing the same ingredient.

For patients, however, the relevant comparison must go beyond the brand name. The medicine’s active ingredient, strength, dosage form, route of administration, approved indication and quality standards need to be considered. An oral tablet and an injectable formulation are not automatically interchangeable simply because they contain the same active ingredient.

For cancer treatment, patients should not replace a prescribed medicine with a cheaper alternative without consulting their oncologist or pharmacist. A lower-priced product may be a suitable option, but that decision must be based on clinical appropriateness and verified product information rather than price alone.

Patent protection and limited competition

Another factor is the level of competition in the market. Some older cancer medicines have multiple manufacturers, while newer therapies may have fewer suppliers because of patent protection, regulatory barriers, manufacturing complexity or the specialised expertise required to produce them.

Patent protection can give a company a period of market exclusivity for an invention, subject to the applicable law and the specific patent rights involved. During this period, the number of competing products may be limited. When competition is weak, a manufacturer may have greater pricing power, although the actual price remains influenced by regulation, reimbursement arrangements, purchasing contracts and market demand.

The situation can be particularly challenging with advanced cancer treatments, including certain targeted therapies and immunotherapies. These medicines may involve complex development programmes, specialised manufacturing processes and expensive clinical research. Their prices may also reflect the commercial expectations associated with a relatively small patient population.

Research and development costs are part of the pharmaceutical industry’s economic argument for high prices, but they do not explain every price difference on their own. Marketing strategies, market exclusivity, competition, procurement arrangements and regulatory status can all influence the amount charged.

When competing manufacturers enter a market, prices may change. However, the speed and extent of that change depend on how many suppliers are available, whether they can meet demand and how effectively hospitals and patients can access the alternatives.

Manufacturing, formulation and supply-chain costs

Even when two products contain the same active ingredient, their production costs may differ. Pharmaceutical manufacturing requires raw materials, quality-control procedures, specialised equipment, packaging, storage and compliance with manufacturing standards. Certain cancer medicines require sterile production environments, specialised handling or controlled storage conditions.

The cost of active pharmaceutical ingredients can also vary according to their source and availability. Manufacturers may face differences in freight charges, energy costs, packaging materials, currency movements and procurement contracts. These factors can influence the final price, although their impact varies by product and manufacturer.

Supply-chain arrangements introduce further differences. A medicine purchased directly through a hospital procurement contract may have a different effective cost from one obtained through a retail pharmacy. Hospitals may negotiate bulk-purchase discounts, while smaller outlets may purchase through several layers of distributors. Stock availability can also influence which products are offered to patients.

Nevertheless, a higher price should not automatically be interpreted as evidence of superior quality, just as a lower price should not automatically be interpreted as evidence of inferior quality. The comparison must be based on verified product information, applicable standards and the actual terms of sale.

Hospital pharmacies and retail pharmacies

The location where a patient obtains a medicine can influence the final bill. Hospitals may procure medicines through negotiated arrangements, maintain their own pharmacy systems or provide medicines as part of a treatment package. Retail pharmacies operate through different purchasing and distribution arrangements, and their available brands may differ.

A patient may therefore receive one price from a hospital pharmacy and another from an outside retailer. The difference can reflect procurement discounts, stock availability, the selected brand, pack size or the way the bill has been structured. In some cases, a patient may also be comparing the medicine’s printed maximum retail price with a discounted selling price rather than comparing two actual transaction prices.

A meaningful comparison should establish whether both prices refer to the same medicine, the same strength, the same quantity and the same formulation. It should also distinguish the medicine’s price from hospital administration charges, infusion services, consumables, consultation fees and other treatment-related expenses.

These distinctions matter because a lower price for the medicine itself does not necessarily translate into a lower total treatment bill. Conversely, a hospital’s overall package may include services that are charged separately elsewhere.

What Does the Latest Cancer Drug Price Regulation Mean?

India’s regulatory framework has continued to evolve. In a written reply published by the Press Information Bureau on February 3, 2026, the government stated that the NPPA had fixed ceiling prices for 131 scheduled anti-cancer formulations and had also fixed retail prices for new drugs within the relevant regulatory framework. The statement explained that non-scheduled formulations are monitored under DPCO provisions that restrict increases in maximum retail prices to no more than 10% over the preceding 12 months.

These measures are important because they clarify a common misconception: cancer medicines are not simply divided into products that are regulated and products that are completely beyond government oversight. Different regulatory mechanisms may apply depending on the medicine and its status under the DPCO.

The government has also reported savings associated with changes in the ceiling prices of essential cancer medicines. In March 2026, it stated that 131 anti-cancer drugs had effective ceiling prices and that revisions had reduced ceiling prices by approximately 21% compared with those established under the NLEM 2015 framework, with estimated annual savings of around ₹294 crore for patients.

At the same time, the NPPA’s official updates dated October 27 and October 28, 2026, list revised maximum retail prices for non-scheduled anti-cancer medicines to take effect from November 9, 2026. The authority has also published a notification concerning trade-margin rationalisation for these medicines. Since the stated effective date is in the future as of October 29, these revisions should be understood as announced measures rather than changes that have already taken effect.

These developments demonstrate that regulation can evolve in response to affordability concerns. They also highlight why patients, hospitals and pharmacies need to check the latest applicable notifications instead of relying on old price lists or general assumptions about cancer medicines.

How Patients Can Check Whether a Cancer Medicine Is Fairly Priced

Compare the medicine’s exact details

Patients and caregivers can begin by checking the generic name, strength, dosage form, pack size and manufacturer on the prescription and medicine packaging. They should then compare the available products using those details rather than relying solely on similar brand names.

The NPPA publishes price notifications and information about regulated medicines through its official website. Patients can consult these resources to determine whether a relevant ceiling price or retail price applies. The authority’s official website also provides a helpline at 1800-11-1255, available on working days from 10 a.m. to 6 p.m., for price-related enquiries.

If a medicine appears to be priced above its applicable permitted limit, the patient can retain the bill, packaging details and price information and seek clarification from the pharmacy or the relevant authority. A difference between two brands does not itself establish overcharging; the applicable regulation and product details must first be verified.

Ask about clinically appropriate lower-cost options

Patients can ask their oncologist whether a lower-priced generic or another approved product is clinically suitable. The discussion should consider the active ingredient, formulation, treatment protocol, availability and any relevant patient-specific requirements. The objective is to reduce financial pressure without compromising treatment.

Patients should also ask whether the hospital offers financial assistance, manufacturer-supported patient programmes or access to public healthcare schemes for which they may qualify. Availability and eligibility vary, so any programme should be verified directly with the hospital, government authority or programme provider.

A written estimate of treatment costs can help families understand how much is attributable to medicines and how much to hospital services, diagnostic tests, administration and follow-up care. This makes it easier to identify where savings may be possible and where further clarification is needed.

The Policy Challenge: Affordability Without Compromising Access

Medicine price control must balance several objectives. Patients need affordable treatment, manufacturers need a viable environment for producing medicines, and the healthcare system needs reliable access to effective therapies. A policy that focuses exclusively on lowering prices without considering supply could create availability problems, while a system that relies only on market competition may leave patients exposed to high costs where competition is limited.

Price ceilings can protect patients against excessive prices for covered medicines, but their impact depends on effective enforcement, transparent information and the availability of products in the market. Regulation must also adapt as new therapies emerge and the costs of treatment change.

Greater transparency could help patients and hospitals compare prices more effectively. Clearer product-level information, accessible official price databases and stronger monitoring of overcharging could reduce confusion. Hospital procurement practices may also benefit from transparent comparisons that consider both price and reliable supply.

India’s generic manufacturing capacity offers an important foundation for improving affordability. However, generic availability alone cannot solve every problem, particularly where medicines are protected by patents, require complex manufacturing or have few competing suppliers. Wider access may require a combination of price regulation, competition, public procurement, insurance coverage and financial assistance.

Conclusion: The Same Medicine, Different Prices—and the Need for Transparency

The same cancer drug can have different prices in India because pharmaceutical pricing is shaped by several interconnected factors, including branding, competition, patent protection, manufacturing expenses, distribution arrangements and the specific rules that apply to a medicine. Price-control mechanisms reduce the scope for excessive pricing in covered categories, but they do not automatically make every brand, pharmacy and treatment package identical in cost.

India’s framework, administered through the NPPA and the DPCO, provides important safeguards through ceiling prices, retail-price regulation and monitoring of non-scheduled formulations. Recent changes to cancer medicine pricing show that affordability remains an active policy concern. However, effective protection also depends on patients being able to find reliable price information, authorities enforcing applicable limits and healthcare providers explaining available options.

For families dealing with cancer, price transparency is more than a consumer issue. It can influence whether treatment remains financially manageable over time. Patients should be able to understand what they are paying for, identify the applicable regulatory protections and discuss clinically appropriate alternatives with their healthcare team.

Ultimately, fair medicine pricing requires more than a government ceiling or a competitive pharmaceutical market. It requires a system in which regulation, reliable supply, transparent billing and access to appropriate treatment work together so that financial uncertainty does not become an additional barrier to cancer care.